Business Standard

Wockhardt, Serum Institute of India tie up to make vaccines in UK

SII has supplied the AstraZeneca-Oxford vaccine to the UK already, and having a fill-and-finish facility in the UK would help the firm to have closer access to the UK and EU markets.

Zydus vaccine

Photo: Bloomberg

Sohini Das Mumbai
Mumbai-based Wockhardt and Serum Life Sciences, a subsidiary of Serum Institute of India (SII), have entered into a partnership to make 150 million doses of SII vaccines in Wockhardt’s UK plant.
“This is a profit-sharing arrangement whereby we are setting up a new facility at Wrexham in North Wales. The investment on the facility is a joint venture between the two partners. It will be able to make 150 million doses of any SII vaccine for which they deliver the drug substance to us,” Habil Khorakiwala, chairman, Wockhardt, told Business Standard. 
This will be a fill-and-finish facility for vaccines.

Don't miss the most important news and views of the day. Get them on our Telegram channel

First Published: Mar 20 2022 | 11:57 PM IST

Explore News

To read the full story, subscribe to BS Premium now, at just Rs 249/ month.

Key stories on are available only to BS Premium subscribers.

Register to